RITE AID CORP - Quarter Report: 2018 September (Form 10-Q)

Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

x      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 1, 2018

 

OR

 

o         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from               to               

 

Commission File Number: 1-5742

 

RITE AID CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Registrant’s telephone number, including area code: (717) 761-2633.

 

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report):

Not Applicable

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “Large Accelerated Filer,” “Accelerated Filer,” “Smaller Reporting Company” and “Emerging Growth Company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer x

Accelerated Filer o

Non-Accelerated Filer o

Smaller reporting company o Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange act).  Yes o  No x

 

The registrant had 1,066,574,198 shares of its $1.00 par value common stock outstanding as of September 27, 2018.

 

 

Table of Contents

 

RITE AID CORPORATION

 

TABLE OF CONTENTS

 

	Cautionary Statement Regarding Forward-Looking Statements	3
PART I FINANCIAL INFORMATION
ITEM 1.	Financial Statements (unaudited):
	Condensed Consolidated Balance Sheets as of September 1, 2018 and March 3, 2018	5
	Condensed Consolidated Statements of Operations for the Thirteen Week Periods Ended September 1, 2018 and September 2, 2017	6
	Condensed Consolidated Statements of Comprehensive (Loss) Income for the Thirteen Week Periods Ended September 1, 2018 and September 2, 2017	7
	Condensed Consolidated Statements of Operations for the Twenty-Six Week Periods Ended September 1, 2018 and September 2, 2017	8
	Condensed Consolidated Statements of Comprehensive (Loss) Income for the Twenty-Six Week Periods Ended September 1, 2018 and September 2, 2017	9
	Condensed Consolidated Statements of Cash Flows for the Twenty-Six Week Periods Ended September 1, 2018 and September 2, 2017	10
	Notes to Condensed Consolidated Financial Statements	11
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	37
ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	50
ITEM 4.	Controls and Procedures	50
PART II OTHER INFORMATION
ITEM 1.	Legal Proceedings	51
ITEM 1A.	Risk Factors	51
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	51
ITEM 3.	Defaults Upon Senior Securities	51
ITEM 4.	Mine Safety Disclosures	51
ITEM 5.	Other Information	51
ITEM 6.	Exhibits	51

 

2

Table of Contents

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

This report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will” and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies.

 

Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

 

·                  our high level of indebtedness;

 

·                  our ability to make interest and principal payments on our debt and satisfy the other covenants contained in our credit facility and other debt agreements;

 

·                  the impact of private and public third party payors continued reduction in prescription drug reimbursement rates and their ongoing efforts to limit access to payor networks, including through mail order;

 

·                  our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs, and our ability to achieve drug pricing efficiencies;

 

·                  the impact of the loss of one or more major third party payor contracts;

 

·                  the inability to complete the sale of distribution centers to Walgreens Boots Alliance, Inc. (“WBA”), receive the related proceeds and recognize the corresponding expected gain due to the failure to satisfy the minimal remaining conditions applicable only to the distribution centers being transferred at such distribution center closing;

 

·                  the risk that the terminated merger (the “Merger”) with Albertsons Companies, Inc. (“Albertsons”) could have an adverse effect on our ability to retain customers and retain and hire key personnel and maintain relationships with our suppliers and customers and on our operating results and businesses generally;

 

·                  the impact on our business, operating results and relationships with customers, suppliers, third party payors, and employees, resulting from our efforts over the past three years to consummate a significant transaction with WBA and Albertsons;

 

·                  the risk that we will not be able to meet our obligations under our Transition Services Agreement (“TSA”) with WBA, which could expose us to significant financial penalties;

 

·                  the risk that we cannot reduce our selling, general and administrative expenses enough to offset lost revenue from the TSA agreement as the amount of stores serviced under the agreement decreases;

 

·                  the risk that there may be changes to our strategy due to the termination of the Merger, or if the remaining distribution center closing of the Sale do not close, which may include delaying or reducing capital or other expenditures, selling assets or other operations, closing underperforming stores, attempting to restructure or refinance our debt, seeking additional capital or incurring other costs associated with restructuring our business, any of which could have an impact on our stock price;

 

·                  the risk that we may need to take further impairment charges if our future results do not meet our expectations;

 

·                  our ability to refinance our indebtedness on terms favorable to us;

 

·                  our ability to improve the operating performance of our stores in accordance with our long term strategy;

 

·                  our ability to grow prescription count and realize front-end sales growth;

 

·                  our ability to hire and retain qualified personnel;

 

3

Table of Contents

 

·                  decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in charges to our operating statement;

 

·                  our ability to manage expenses and working capital and our ability to achieve our drug purchasing initiatives;

 

·                  continued consolidation of the drugstore and the pharmacy benefit management (“PBM”) industries;

 

·                  the risk that changes in federal or state laws or regulations, including the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or “Patient Care Act”) and any regulations enacted thereunder may occur;

 

·                  the risk that provider and state contract changes may occur;

 

·                  risks related to compromises of our information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

 

·                  our ability to maintain our current pharmacy services business and obtain new pharmacy services business, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration and early price renegotiations prior to contract expirations;

 

·                  the continued impact of gross margin pressure in the PBM industry due to increased market competition and client demand for lower prices while providing enhanced service offerings;

 

·                  our ability to maintain our current Medicare Part D business and obtain new Medicare Part D business, as a result of the annual Medicare Part D competitive bidding process;

 

·                  the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

 

·                  risks related to other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies or competitive development including aggressive promotional activity from our competitors;

 

·                  the risk that we could experience deterioration in our current Star rating with the Centers of Medicare and Medicaid Services (“CMS”) or incur CMS penalties and/or sanctions;

 

·                  the nature, cost and outcome of pending and future litigation and other legal proceedings or governmental investigations, including any such proceedings related to the Merger or Sale and instituted against us and others;

 

·                  the potential reputational risk to our business during the period in which WBA is operating the Acquired Stores (as defined below) under the Rite Aid banner;

 

·                  the risk that the Tax Cuts and Jobs Act that was enacted on December 22, 2017 may have a negative impact on our financial results;

 

·                  the inability to fully realize the benefits of our tax attributes;

 

·                  other risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission (the “SEC”).

 

We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included herein and in our Annual Report on Form 10-K for the fiscal year ended March 3, 2018 (the “Fiscal 2018 10-K”), which we filed with the SEC on April 26, 2018, and our Quarterly Report on Form 10-Q for the thirteen weeks ended June 2, 2018 (the “First Quarter 2019 10-Q”) which we filed on July 6, 2018, as well as in the “Risk Factors” section of the Fiscal 2018 10-K. These documents are available on the SEC’s website at www.sec.gov.

 

4

Table of Contents

 

PART I. FINANCIAL INFORMATION

 

ITEM 1.  Financial Statements

 

RITE AID CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(In thousands, except per share amounts)

 

(unaudited)

 

		September 1, 2018			March 3, 2018
ASSETS
Current assets:
Cash and cash equivalents		$	132,468		$	447,334
Accounts receivable, net		2,039,605			1,869,100
Inventories, net of LIFO reserve of $594,413 and $581,090		1,848,287			1,799,539
Prepaid expenses and other current assets		169,313			181,181
Current assets held for sale		181,989			438,137
Total current assets		4,371,662			4,735,291
Property, plant and equipment, net		1,350,735			1,431,246
Goodwill		1,108,135			1,421,120
Other intangibles, net		480,520			590,443
Deferred tax assets		635,127			594,019
Other assets		219,489			217,208
Total assets		$	8,165,668		$	8,989,327
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current maturities of long-term debt and lease financing obligations		$	18,668		$	20,761
Accounts payable		1,733,989			1,651,363
Accrued salaries, wages and other current liabilities		938,940			1,231,736
Current liabilities held for sale		—			560,205
Total current liabilities		2,691,597			3,464,065
Long-term debt, less current maturities		3,481,741			3,340,099
Lease financing obligations, less current maturities		26,537			30,775
Other noncurrent liabilities		509,843			553,378
Total liabilities		6,709,718			7,388,317
Commitments and contingencies		—			—
Stockholders’ equity:
Common stock, par value $1 per share; 1,500,000 shares authorized; shares issued and outstanding 1,066,050 and 1,067,318		1,066,050			1,067,318
Additional paid-in capital		4,859,462			4,850,712
Accumulated deficit		(4,435,741		)	(4,282,471		)
Accumulated other comprehensive loss		(33,821		)	(34,549		)
Total stockholders’ equity		1,455,950			1,601,010
Total liabilities and stockholders’ equity		$	8,165,668		$	8,989,327

 

See accompanying notes to condensed consolidated financial statements.

 

5

Table of Contents

 

RITE AID CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(In thousands, except per share amounts)

 

(unaudited)

 

		Thirteen Week Period Ended
		September 1, 2018			September 2, 2017
Revenues		$	5,421,362		$	5,345,011
Costs and expenses:
Cost of revenues		4,260,211			4,183,338
Selling, general and administrative expenses		1,153,991			1,141,844
Lease termination and impairment charges		39,609			3,113
Goodwill and intangible asset impairment charges		375,190			—
Interest expense		56,233			50,857
Walgreens Boots Alliance merger termination fee		—			(325,000		)
Gain on sale of assets, net		(4,965		)	(14,951		)
		5,880,269			5,039,201
(Loss) income from continuing operations before income taxes		(458,907		)	305,810
Income tax (benefit) expense		(106,559		)	117,450
Net (loss) income from continuing operations		(352,348		)	188,360
Net loss from discontinued operations, net of tax		(6,792		)	(17,644		)
Net (loss) income		$	(359,140	)	$	170,716
Computation of (loss) income attributable to common stockholders:
(Loss) income from continuing operations attributable to common stockholders—basic and diluted		$	(352,348	)	$	188,360
Loss from discontinued operations attributable to common stockholders—basic and diluted		(6,792		)	(17,644		)
(Loss) income attributable to common stockholders—basic and diluted		$	(359,140	)	$	170,716
Basic and diluted (loss) income per share:
Continuing operations		$	(0.33	)	$	0.18
Discontinued operations		$	(0.01	)	$	(0.02	)
Net basic and diluted (loss) income per share		$	(0.34	)	$	0.16

 

See accompanying notes to condensed consolidated financial statements.

 

6

Table of Contents

 

RITE AID CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

 

(In thousands)

 

(unaudited)

 

		Thirteen Week Period Ended
		September 1, 2018			September 2, 2017
Net (loss) income		$	(359,140	)	$	170,716
Other comprehensive income:
Defined benefit pension plans:
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of $144 and $342 tax expense		364			515
Total other comprehensive income		364			515
Comprehensive (loss) income		$	(358,776	)	$	171,231

 

See accompanying notes to condensed consolidated financial statements.

 

7

Table of Contents

 

RITE AID CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

(In thousands, except per share amounts)

 

(unaudited)

 

		Twenty-Six Week Period Ended
		September 1, 2018			September 2, 2017
Revenues		$	10,809,852		$	10,781,534
Costs and expenses:
Cost of revenues		8,479,952			8,457,918
Selling, general and administrative expenses		2,306,618			2,302,784
Lease termination and impairment charges		49,468			7,151
Goodwill and intangible asset impairment charges		375,190			—
Interest expense		119,025			101,857
Loss on debt retirements, net		554			—
Walgreens Boots Alliance merger termination fee		—			(325,000		)
Gain on sale of assets, net		(10,824		)	(20,828		)
		11,319,983			10,523,882
(Loss) income from continuing operations before income taxes		(510,131		)	257,652
Income tax (benefit) expense		(116,056		)	105,329
Net (loss) income from continuing operations		(394,075		)	152,323
Net income (loss) from discontinued operations, net of tax		249,351			(56,956		)
Net (loss) income		$	(144,724	)	$	95,367
Computation of (loss) income attributable to common stockholders:
(Loss) income from continuing operations attributable to common stockholders—basic and diluted		$	(394,075	)	$	152,323
Income (loss) from discontinued operations attributable to common stockholders—basic and diluted		249,351			(56,956		)
(Loss) income attributable to common stockholders—basic and diluted		$	(144,724	)	$	95,367
Basic and diluted (loss) income per share:
Continuing operations		$	(0.37	)	$	0.14
Discontinued operations		$	0.23		$	(0.05	)
Net basic and diluted (loss) income per share		$	(0.14	)	$	0.09

 

See accompanying notes to condensed consolidated financial statements.

 

8

Table of Contents

 

RITE AID CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

 

(In thousands)

 

(unaudited)

 

		Twenty-Six Week Period Ended
		September 1, 2018			September 2, 2017
Net (loss) income		$	(144,724	)	$	95,367
Other comprehensive income:
Defined benefit pension plans:
Amortization of prior service cost, net transition obligation and net actuarial losses included in net periodic pension cost, net of $288 and $684 tax expense		728			1,029
Total other comprehensive income		728			1,029
Comprehensive (loss) income		$	(143,996	)	$	96,396

 

See accompanying notes to condensed consolidated financial statements.

 

9

Table of Contents

 

RITE AID CORPORATION AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(In thousands)

 

(unaudited)

 

		Twenty-Six Week Period Ended
		September 1, 2018			September 2, 2017
Operating activities:
Net (loss) income		$	(144,724	)	$	95,367
Net income (loss) from discontinued operations, net of tax		249,351			(56,956		)
Net (loss) income from continuing operations		$	(394,075	)	$	152,323
Adjustments to reconcile to net cash (used in) provided by operating activities of continuing operations:
Depreciation and amortization		184,272			196,684
Lease termination and impairment charges		49,468			7,151
Goodwill and intangible asset impairment charges		375,190			—
LIFO charge		13,324			13,609
Gain on sale of assets, net		(10,824		)	(20,828		)
Stock-based compensation expense		10,246			15,362
Loss on debt retirements, net		554			—
Changes in deferred taxes		(124,807		)	64,850
Changes in operating assets and liabilities:
Accounts receivable		(323,724		)	(88,748		)
Inventories		(31,650		)	(27,454		)
Accounts payable		207,943			59,271
Other assets		(11,232		)	(14,262		)
Other liabilities		(245,587		)	(62,485		)
Net cash (used in) provided by operating activities of continuing operations		(300,902		)	295,473
Investing activities:
Payments for property, plant and equipment		(92,565		)	(79,116		)
Intangible assets acquired		(20,519		)	(9,679		)
Proceeds from insured loss		—			3,627
Proceeds from dispositions of assets and investments		15,729			17,407
Proceeds from sale-leaseback transactions		2,587			—
Net cash used in investing activities of continuing operations		(94,768		)	(67,761		)
Financing activities:
Net proceeds from (payments to) revolver		1,335,000			(190,000		)
Principal payments on long-term debt		(433,746		)	(4,386		)
Change in zero balance cash accounts		(17,101		)	10,189
Net proceeds from issuance of common stock		1,302			215
Payments for taxes related to net share settlement of equity awards		(2,244		)	(4,071		)
Financing fees paid for early debt redemption		(13		)	—
Net cash provided by (used in) financing activities of continuing operations		883,198			(188,053		)
Cash flows from discontinued operations:
Operating activities of discontinued operations		(62,003		)	2,358
Investing activities of discontinued operations		603,402			(44,739		)
Financing activities of discontinued operations		(1,343,793		)	(3,710		)
Net cash used in discontinued operations		(802,394		)	(46,091		)
Decrease in cash and cash equivalents		(314,866		)	(6,432		)
Cash and cash equivalents, beginning of period		447,334			245,410
Cash and cash equivalents, end of period		$	132,468		$	238,978

 

See accompanying notes to condensed consolidated financial statements.

 

10

Table of Contents

 

RITE AID CORPORATION AND SUBSIDIARIES

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

For the Thirteen and Twenty-Six Week Periods Ended September 1, 2018 and September 2, 2017

 

(Dollars and share information in thousands, except per share amounts)

 

(unaudited)

 

1. Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen and twenty-six week periods ended September 1, 2018 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation (“Rite Aid”) and Subsidiaries (together with Rite Aid, the “Company”) Fiscal 2018 10-K.

 

The discussion and presentation of the operating and financial results of our business segments have been impacted by the following event.

 

Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement (the “Amended and Restated Asset Purchase Agreement”), dated as of September 18, 2017, by and among Rite Aid, WBA and Walgreen Co., an Illinois corporation and wholly owned direct subsidiary of WBA (“Buyer”), Buyer agreed to purchase from Rite Aid 1,932 stores (the “Acquired Stores”), three distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of approximately $4,375,000, on a cash free, debt free basis (the “Asset Sale” or the “Sale”). As of March 27, 2018, the Company has sold all 1,932 Acquired Stores and related assets to WBA in exchange for proceeds of $4,156,686, which were used to repay outstanding debt. Based on its magnitude and because the Company is exiting certain markets, the Sale represents a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Asset Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the assets and liabilities to be sold, including the 1,932 Acquired Stores, three (3) distribution centers, related inventory and other specified assets and liabilities related thereto (collectively the “Assets to be Sold” or “Disposal Group”) to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended September 1, 2018 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. Additionally, corporate support activities related to the Disposal Group were not reclassified to discontinued operations. Please see additional information as provided in Note 3 Asset Sale to WBA.

 

Recently Adopted Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU No. 2014-09 outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In March 2016, the FASB issued ASU No. 2016-08, “Principal Versus Agent Considerations (Reporting Revenue Gross Versus Net),” which amends the principal-versus-agent implementation guidance and in April 2016, the FASB issued ASU No. 2016-10, “Identifying Performance Obligations and Licensing,” which amends the guidance in those areas in the new revenue recognition standard. These ASUs, collectively the “new revenue standard”, are effective for annual reporting periods (including interim reporting periods within those periods) beginning January 1, 2018.

 

The Company adopted the new revenue standard as of March 4, 2018 using the modified retrospective method and applying the new standard to all contracts with customers.  Therefore, the comparative financial information has not been restated and continues to be reported under the accounting standards in effect for those periods.  In connection with the adoption of the new revenue standard, the Company identified one difference in its Retail Pharmacy segment related to the timing of revenue recognition for third party prescription revenues, which was historically recognized at the time the prescription was filled.  Upon adoption of ASU No. 2014-09, this revenue is recognized at the time the customer takes possession of the merchandise. In connection with its March 4, 2018 adoption of the new revenue standard on a modified retrospective basis, the Company recorded a reduction to accounts receivable of $57,897, a reduction to deferred tax assets of $1,772, an increase to inventory of $51,121, and a corresponding increase to accumulated deficit of $8,548 within its Retail Pharmacy segment.

 

11

Table of Contents

 

In addition, the Company identified revenues under one specific rebate administration program under which the Company’s Pharmacy Services segment was determined to be the principal and historically recognized revenues and cost of revenues on a gross basis of approximately $123,500 during fiscal 2018. Upon adoption of the new revenue standard, the Company is now recording revenue from this program on a net basis.

 

The following is a discussion of the Company’s revenue recognition policies by segment under the new revenue recognition accounting standard:

 

Revenue Recognition

 

Retail Pharmacy Segment

 

For front end sales, the Retail Pharmacy segment recognizes revenues upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation at the point of sale for front end transactions. The Retail Pharmacy segment front end revenue is measured based on the amount of fixed consideration that we expect to receive, net of an allowance for estimated future returns. Return activity is immaterial to revenues and results of operations in all periods presented.

 

For pharmacy sales, the Retail Pharmacy segment recognizes revenue upon the transfer of control of the goods to the customer. The Company satisfies its performance obligation, upon pickup by the customer, which is when the customer takes title to the product.  Each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims.  The Company’s revenue is measured based on the amount of fixed consideration that we expect to receive, reduced by refunds owed to the third party payor for pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not highly subjective or volatile.  The effect of adjustments between estimated and actual amounts have not been material to the Company’s results of operations or financial position. Prescriptions are generally not returnable.

 

The Retail Pharmacy segment offers a chain-wide loyalty card program titled wellness +. Individual customers are able to become members of the wellness + program.  Members participating in the wellness + loyalty card program earn points on a calendar year basis for eligible front end merchandise purchases and qualifying prescription purchases.  One point is awarded for each dollar spent towards front end merchandise and 25 points are awarded for each qualifying prescription.

 

Members reach specific wellness + tiers based on the points accumulated during the calendar year, which entitles such customers to certain future discounts and other benefits upon reaching that tier. For example, any customer that reaches 1,000 points in a calendar year achieves the “Gold” tier, enabling him or her to receive a 20% discount on qualifying purchases of front end merchandise for the remaining portion of the calendar year and also the next calendar year. There is also a similar “Silver” level with a lower threshold and benefit level.

 

Points earned pursuant to the wellness+ program represent a performance obligation and the Company allocates revenue between the merchandise purchased and the wellness + points based on the relative stand-alone selling price of each performance obligation. The relative value of the wellness + points is initially deferred as a contract liability (included in other current and noncurrent liabilities). As customers redeem the points to receive discounted front end merchandise or when the points expire, the Retail Pharmacy segment recognizes an allocable portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $68,426 as of September 1, 2018, of which $51,916 is included in other current liabilities and $16,510 is included in noncurrent liabilities. The Retail Pharmacy segment had accrued contract liabilities of $63,851 as of March 3, 2018, of which $50,036 is included in other current liabilities and $13,815 is included in noncurrent liabilities.

 

The wellness + program also allows a customer to earn Bonus Cash based on qualifying purchases. Wellness + Rewards members have the opportunity to redeem their accumulated Bonus Cash on a future purchase with a 60 day expiration window.

 

For a majority of the Bonus Cash issuances, funding is provided by our vendors through contractual arrangements. This funding is treated as a contract liability and remains a contract liability until (i) wellness + Rewards members redeem their Bonus Cash, or (ii) wellness + Rewards members allow the Bonus Cash to expire. Upon redemption or expiration, the Retail Pharmacy segment recognizes an allocable portion of the accrued contract liability into revenue. For Bonus Cash issuances that are not vendor funded, the contract liability is recorded at the time of issuance through a reduction to revenues, and not recognized until the Bonus Cash is redeemed or expires.

 

12

Table of Contents

 

Pharmacy Services Segment

 

The Pharmacy Services segment sells prescription drugs indirectly through its retail pharmacy network and directly through its mail service dispensing pharmacy. The Pharmacy Services segment recognizes revenue from prescription drugs sold by (i) its mail service dispensing pharmacy and (ii) under retail pharmacy network contracts where it is the principal at the contract prices negotiated with its clients, primarily employers, insurance companies, unions, government employee groups, health plans, Managed Medicaid plans, Medicare plans, and other sponsors of health benefit plans, and individuals throughout the United States. Revenues include: (i) the portion of the price the client pays directly to the Pharmacy Services segment, net of any volume-related or other discounts paid back to the client (see “Drug Discounts” below), (ii) the price paid to the Pharmacy Services segment by client plan members for mail order prescriptions (“Mail Co-Payments”) (iii) client plan member copayments made directly to the retail pharmacy network, and (iv) administrative fees. Revenue is recognized when the Pharmacy Services segment meets its performance obligations relative to each transaction type. The following revenue recognition policies have been established for the Pharmacy Services segment:

 

·                  Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services segment’s online claims processing system.  At this point the Company has performed all of its performance obligations.

 

·                  Revenues generated from prescription drugs sold by the Pharmacy Services segment’s mail service dispensing pharmacy are recognized when the prescription is shipped. At the time of shipment, the Pharmacy Services segment has performed all of its performance obligations under its client contracts, as control of and title to the product has passed to the clients plan member.  The Pharmacy Services segment does not experience a significant level of returns or reshipments.

 

·                  Revenues generated from administrative fees based on membership or claims volume are recognized monthly based on the terms within the individual contracts, either a monthly member based fee, or a claims volume based fee.

 

In the majority of its contracts, the Pharmacy Services segment is the principal because its client contracts give clients the right to obtain access to its pharmacy contracts under which the Pharmacy Services segment directs its pharmacy network to provide the services (drug dispensing, consultation, etc.) and goods (prescription drugs) to the clients’ members at its negotiated pricing. The Pharmacy Services segment’s obligations under its client contracts are separate and distinct from its obligations to the third party pharmacies included in its retail pharmacy network contracts. Pursuant to these contracts, the Pharmacy Services segment is contractually required to pay the third party pharmacies in its retail pharmacy network for products sold after payment is received from its clients. The Pharmacy Services segment has control over these transactions until the prescription is transferred to the member and, thus, that it is acting as a principal. As such, the Pharmacy Services segment records the total prescription price contracted with clients in revenues.

 

Amounts paid to pharmacies and amounts charged to clients are exclusive of the applicable co-payment under Pharmacy Services segment contracts. Retail pharmacy co-payments, which we instruct retail pharmacies to collect from members, are included in our revenues and our cost of revenues.

 

For contracts under which the Pharmacy Services segment acts as an agent or does not control the prescription drugs prior to transfer to the client, no revenue is recognized.

 

Drug Discounts—The Pharmacy Services segment deducts from its revenues that are generated from prescription drugs sold by third party pharmacies any rebates, inclusive of discounts and fees, earned by its clients based on utilization levels and other factors as negotiated with the prescription drug manufacturers or suppliers. Rebates are paid to clients in accordance with the terms of client contracts.

 

Medicare Part D—The Pharmacy Services segment, through its EIC subsidiary, participates in the federal government’s Medicare Part D program as a Prescription Drug Plan (“PDP”). Please refer to Note 8, Medicare Part D.

 

13

Table of Contents

 

Disaggregation of Revenue

 

The following tables disaggregate the Company’s revenue by major source in each segment for the thirteen and twenty-six week periods ended September 1, 2018:

 

In thousands		For the thirteen week period ended September 1, 2018			For the twenty-six week period ended September 1, 2018
Retail Pharmacy segment:
Pharmacy sales		$	2,573,909		$	5,139,194
Front end sales		1,301,062			2,597,209
Other revenue		36,541			72,874
Total Retail Pharmacy segment		$	3,911,512		$	7,809,277
Pharmacy Services segment		1,561,811			3,104,573
Intersegment elimination		(51,961		)	(103,998		)
Total revenue		$	5,421,362		$	10,809,852

 

Impact of New Revenue Recognition Standard on Financial Statement Line Items

 

The Company adopted the new revenue standard using the modified retrospective method. The cumulative effect of applying the new standard to all contracts was recorded as an adjustment to accumulated deficit as of the adoption date. As a result of applying the modified retrospective method to adopt the new revenue standard, the following adjustments were made to accounts on the condensed consolidated balance sheet as of March 4, 2018:

 

		Impact of Change in Accounting Policy
		As Reported						Adjusted
In thousands		March 3, 2018			Adjustments			March 4, 2018
Condensed Consolidated Balance Sheet:
Accounts receivable, net		$	1,869,100		$	(57,897	)	$	1,811,203
Inventories, net		1,799,539			51,121			1,850,660
Deferred tax assets		594,019			(1,772		)	592,247
Total assets		8,989,327			(8,548		)	8,980,779
Accumulated deficit		(4,282,471		)	(8,548		)	(4,291,019		)
Total shareholders’ equity		1,601,010			(8,548		)	1,592,462

 

Reclassification of the Statements of Cash Flows presentation

 

During the thirteen week period ended September 1, 2018, the Company expanded its disclosure on its Statements of Cash Flows to include changes in other assets separate from changes in other liabilities, which had historically been combined.  Prior period amounts have been reclassified to conform to the current period presentation.

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In February 2016, the FASB issued ASU No. 2016-02, Leases, (Topic 842), which is intended to improve financial reporting around leasing transactions. The ASU affects all companies and other organizations that engage in lease transactions (both lessee and lessor) that lease assets such as real estate and manufacturing equipment. This ASU will require organizations that lease assets—referred to as “leases”—to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. ASU No. 2016-02 is effective for fiscal years and interim periods within those years beginning January 1, 2019 (fiscal 2020). During July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements. Among other things, ASU 2018-11 provides administrative relief by allowing entities to implement the lease standard on a modified retrospective basis, similar to the method used by the Company to adopt the revenue standard. Effectively, the modified retrospective basis permits the Company to adopt the lease standard through a cumulative effect adjustment to its opening balance sheet for the first quarter of fiscal 2020, with the cumulative effect accounted for as a component of retained earnings, and report under the new lease standard on a post adoption basis. The Company is currently evaluating the impact this standard implementation will have on its results of operations and cash flows, and we anticipate a material increase in assets and liabilities due to the recording of the required right-of-use asset and corresponding liability for all lease obligations that are currently classified as operating leases.

 

14

Table of Contents

 

2. Termination of the Merger Agreement with Albertsons Companies, Inc.

 

On February 18, 2018, Rite Aid entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Albertsons, Ranch Acquisition II LLC, a Delaware limited liability company and a wholly-owned direct subsidiary of Albertsons (“Merger Sub II”) and Ranch Acquisition Corp., a Delaware corporation and a wholly-owned direct subsidiary of Merger Sub II (“Merger Sub” and, together with Merger Sub II, the “Merger Subs”). On August 8, 2018, Rite Aid, Albertsons and Merger Subs entered into a Termination Agreement (the “Merger Termination Agreement”) under which the parties mutually agreed to terminate the Merger Agreement. Subject to limited customary exceptions, the Merger Termination Agreement mutually releases the parties from any claims of liability to one another relating to the contemplated Merger.  Under the terms of the Merger Agreement, neither Rite Aid nor Albertsons is responsible for any payments to the other party as a result of the termination of the Merger Agreement and Rite Aid is no longer subject to the interim operating covenants and restrictions contained in the Merger Agreement.

 

3. Asset Sale to WBA

 

On September 18, 2017, the Company entered into the Amended and Restated Asset Purchase Agreement with WBA and Buyer, which amended and restated in its entirety the previously disclosed Asset Purchase Agreement (the “Original APA”), dated as of June 28, 2017, by and among the Company, WBA and Buyer. Pursuant to the terms and subject to the conditions set forth in the Amended and Restated Asset Purchase Agreement, Buyer agreed to purchase from the Company 1,932 Acquired Stores, three (3) distribution centers, related inventory and other specified assets and liabilities related thereto for a purchase price of $4,375,000, on a cash-free, debt-free basis in the Sale.

 

The Company announced on September 19, 2017 that the waiting period under the HSR Act, expired with respect to the Sale. As of March 27, 2018, the Company has completed the store transfer process, and all 1,932 stores and related assets have been transferred to WBA and the Company has received cash proceeds of $4,156,686. The transfer of the three (3) distribution centers and related assets is expected to begin after September 1, 2018. The closing conditions related to the asset transfer have been satisfied, and the Company has recorded a pre-tax gain on the Sale of the stores of $2,489,389.

 

On September 13, 2018, the Company completed the sale of one of its distribution centers and related assets to WBA for proceeds of $61,251.  The impact of the sale of the distribution center and related assets will be included in the results of operations and cash flows of discontinued operations during the third quarter ending December 1, 2018.  The transfer of the remaining two distribution centers and related assets remains subject to minimal customary closing conditions applicable only to the distribution centers being transferred at such distribution center closings, as specified in the Amended and Restated Asset Purchase Agreement.

 

The parties to the Amended and Restated Asset Purchase Agreement have each made customary representations and warranties. The Company has agreed to various covenants and agreements, including, among others, the Company’s agreement to conduct its business at the distribution centers being sold to WBA in the ordinary course during the period between the execution of the Amended and Restated Asset Purchase Agreement and the distribution center closing. The Company has also agreed to provide transition services to Buyer for up to three (3) years after the initial closing of the Sale. Under the terms of the TSA, the Company provides various services on behalf of WBA, including but not limited to the purchase and distribution of inventory and virtually all selling, general and administrative activities. In connection with these services, the Company purchases the related inventory and incurs cash payments for the selling, general and administrative activities, which, the Company bills on a cash neutral basis to WBA in accordance with terms as outlined in the TSA. Total billings for these items during the thirteen and twenty-six week periods ended September 1, 2018 were $1,835,484 and $3,876,559, respectively, of which $385,936 is included in Accounts receivable, net. The Company charged WBA TSA fees of $23,213 and $46,948 during the thirteen and twenty-six week periods ended September 1, 2018, respectively, which are reflected as a reduction to selling, general and administrative expenses.

 

Under the terms of the Amended and Restated Asset Purchase Agreement, the Company has the option to purchase pharmaceutical drugs through an affiliate of WBA under terms, including cost, that are substantially equivalent to Walgreen’s for a period of ten (10) years, subject to certain terms and conditions.  The Company has until May of 2019 to exercise this option.

 

Based on its magnitude and because the Company is exiting certain markets, the Sale represented a significant strategic shift that has a material effect on the Company’s operations and financial results. Accordingly, the Company has applied discontinued operations treatment for the Sale as required by Accounting Standards Codification 210-05—Discontinued Operations (ASC 205-20). In accordance with ASC 205-20, the Company reclassified the Disposal Group to assets and liabilities held for sale on its consolidated balance sheets as of the periods ended September 1, 2018 and March 3, 2018, and reclassified the financial results of the Disposal Group in its consolidated statements of operations and consolidated statements of cash flows for all periods presented. The Company also revised its discussion and presentation of operating and financial results to be reflective of its continuing operations as required by ASC 205-20.

 

15

Table of Contents

 

The carrying amount of the Assets to be Sold, which were included in the Retail Pharmacy segment, have been reclassified from their historical balance sheet presentation to current assets and liabilities held for sale as follows:

 

		September 1, 2018			March 3, 2018
Inventories		$	113,523		$	264,286
Property and equipment		68,466			158,433
Goodwill(a)		—			4,629
Intangible assets		—			10,789
Current assets held for sale		$	181,989		$	438,137
Current maturities of long-term lease financing obligations		$	—		$	270
Accrued salaries, wages and other current liabilities		—			6,146
Long-term debt, less current maturities(b)		—			549,549
Lease financing obligations, less current maturities		—			838
Other noncurrent liabilities		—			3,402
Current liabilities held for sale		$	—		$	560,205

 

(a)                                 The Company had $76,124 of goodwill in its Retail Pharmacy segment resulting from the acquisition of Health Dialog and RediClinic, which is accounted for as Retail Pharmacy segment enterprise goodwill. The Company has allocated a portion of its Retail Pharmacy segment enterprise goodwill to the discontinued operation.

 

(b)                                 In connection with the Sale, the Company had estimated that the Sale would generate excess cash proceeds of approximately $4,027,400 which would be used to repay outstanding indebtedness. During the twenty-six week period ended September 1, 2018, the Company has a use of cash for financing purposes of $1,343,793 in its discontinued operations and, based on refinements to its calculations, reduced its estimate of excess cash proceeds by approximately $24,500 and reclassified that amount to assets held and used. Consequently, the Company has classified $0 and $549,549 of estimated cash proceeds to be used for debt repayment to liabilities held for sale as of September 1, 2018 and March 3, 2018, respectively. For the twenty-six week period ended September 1, 2018, the Company repaid outstanding indebtedness of $1,343,793 with Sale proceeds.  For the fifty-two week period ended March 3, 2018, the Company repaid outstanding indebtedness of $3,135,000 with the proceeds from the Sale.

 

The operating results of the discontinued operations that are reflected on the unaudited condensed consolidated statements of operations within net income (loss) from discontinued operations are as follows:

 

		Thirteen Week Period Ended						Twenty-Six Week Period Ended
		September 1, 2018			September 2, 2017			September 1, 2018			September 2, 2017
Revenues		$	4,716		$	2,366,086		$	28,116		$	4,743,943
Costs and expenses:
Cost of revenues(a)		182			1,740,758			17,263			3,521,523
Selling, general and administrative expenses(a)		2,570			592,172			16,445			1,192,812
Lease termination and impairment charges		—			15			—			63
Loss on debt retirements, net		18,075			—			22,645			—
Interest expense (b)		—			60,404			4,615			119,341
Loss (gain) on stores sold to Walgreens Boots Alliance		15			—			(360,542		)	—
Loss on sale of assets, net		11			768			11			612
		20,853			2,394,117			(299,563		)	4,834,351
(Loss) income from discontinued operations before income taxes		(16,137		)	(28,031		)	327,679			(90,408		)
Income tax (benefit) expense		(9,345		)	(10,387		)	78,328			(33,452		)
Net (loss) income from discontinued operations, net of tax		$	(6,792	)	$	(17,644	)	$	249,351		$	(56,956	)

 

16

Table of Contents

 

(a)                                 Cost of revenues and selling, general and administrative expenses for the discontinued operations excludes corporate overhead. These charges are reflected in continuing operations.

 

(b)                                 In accordance with ASC 205-20, the operating results for the thirteen and twenty-six week periods ended September 1, 2018 and September 2, 2017, respectively, for the discontinued operations include interest expense relating to outstanding indebtedness repaid with the estimated excess proceeds from the Sale.

 

The operating results reflected above do not fully represent the Disposal Group’s historical operating results, as the results reported within net income from discontinued operations only include expenses that are directly attributable to the Disposal Group.

 

4. Income (Loss) Per Share

 

Basic income (loss) per share is computed by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company subject to anti-dilution limitations.

 

		Thirteen Week Period Ended						Twenty-Six Week Period Ended
		September 1, 2018			September 2, 2017			September 1, 2018			September 2, 2017
Basic and diluted (loss) income per share:
Numerator:
Net (loss) income from continuing operations		$	(352,348	)	$	188,360		$	(394,075	)	$	152,323
Net (loss) income from discontinued operations, net of tax		(6,792		)	(17,644		)	249,351			(56,956		)
(Loss) income attributable to common stockholders — basic and diluted		$	(359,140	)	$	170,716		$	(144,724	)	$	95,367
Denominator:
Basic weighted average shares		1,056,464			1,048,548			1,055,424			1,047,687
Outstanding options and restricted shares, net		—			18,668			—			22,597
Diluted weighted-average shares		1,056,464			1,067,216			1,055,424			1,070,284
Basic and diluted (loss) income per share:
Continuing operations		$	(0.33	)	$	0.18		$	(0.37	)	$	0.14
Discontinued operations		(0.01		)	(0.02		)	0.23			(0.05		)
Net basic and diluted (loss) income per share		$	(0.34	)	$	0.16		$	(0.14	)	$	0.09

 

Due to their antidilutive effect, 25,163 and 9,206 potential common shares related to stock options have been excluded from the computation of diluted income per share for the thirteen week period ended September 1, 2018 and September 2, 2017, respectively. Due to their antidilutive effect, 25,163 and 5,596 potential common shares related to stock options have been excluded from the computation of diluted income per share for the twenty-six week period ended September 1, 2018 and September 2, 2017, respectively.  Also, excluded from the computation of diluted income per share for the thirteen and twenty-six week periods ended September 1, 2018 and September 2, 2017 are restricted shares of 7,811 and 0, respectively, which are included in shares outstanding.

 

5. Lease Termination and Impairment Charges

 

Lease termination and impairment charges consist of amounts as follows:

 

		Thirteen Week Period Ended						Twenty-Six Week Period Ended
		September 1, 2018			September 2, 2017			September 1, 2018			September 2, 2017
Impairment charges		$	33,562		$	—		$	33,845		$	659
Lease termination charges		6,047			3,113			15,623			6,492
		$	39,609		$	3,113		$	49,468		$	7,151

 

17

Table of Contents

 

Impairment Charges

 

These amounts include the write-down of long-lived assets at locations that were assessed for impairment because of management’s intention to relocate or close the location or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable.

 

During the thirteen week period ended September 1, 2018, due to changes in circumstances at its Retail Pharmacy segment relative to a decline in its current and anticipated operating results and related cash flows as compared to its original projections as announced on August 6, 2018, the Company determined that an active store impairment assessment was required.  Based on the results of the active store impairment assessment, the Company recorded impairment charges of $19,277 relating to 288 active stores.  Additionally, during the thirteen week period ended September 1, 2018, the Company terminated a project to replace the point of sale software in its stores, which resulted in an impairment charge of $14,285 due to the write-off of the related assets.

 

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

 

·                  Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

 

·                  Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

 

·                  Level 3—Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

 

Non-Financial Assets Measured on a Non-Recurring Basis

 

Long-lived non-financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long-lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. During the twenty-six week period ended September 1, 2018, long-lived assets from continuing operations with a carrying value of $40,488, primarily store assets, were written down to their fair value of $6,643, resulting in an impairment charge of $33,845 of which $33,562 relates to the thirteen week period ended September 1, 2018. During the twenty-six week period ended September 2, 2017, long-lived assets from continuing operations with a carrying value of $964, primarily store assets, were written down to their fair value of $305, resulting in an impairment charge of $659. There was no impairment charge in the thirteen week period ended September 2, 2017. If our actual future cash flows differ from our projections materially, certain stores that are either not impaired or partially impaired in the current period may be further impaired in future periods.

 

The table below sets forth by level within the fair value hierarchy the long-lived assets as of the impairment measurement date for which an impairment assessment was performed and total losses as of September 1, 2018 and September 2, 2017:

 

		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Fair Values as of Impairment Date			Total Charges September 1, 2018
Long-lived assets held and used		$	—		$	—		$	6,643		$	6,643		$	(33,562	)
Long-lived assets held for sale		—			1,292			—			1,292			(283		)
Total		$	—		$	1,292		$	6,643		$	7,935		$	(33,845	)

 

		Quoted Prices in Active Markets for Identical Assets (Level 1)			Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Fair Values as of Impairment Date			Total Charges September 2, 2017
Long-lived assets held and used		$	—		$	—		$	201		$	201		$	(211	)
Long-lived assets held for sale		—			104			—			104			(448		)
Total		$	—		$	104		$	201		$	305		$	(659	)

 

18

Table of Contents

 

The above assets reflected in the caption Long-lived assets held for sale are separate and apart from the Assets to be Sold and due to their immateriality, have not been reclassified to assets held for sale.

 

Lease Termination Charges

 

As part of the Company’s ongoing business activities, the Company assesses stores and distribution centers for potential closure or relocation. Decisions to close or relocate stores or distribution centers in future periods would result in lease termination charges, lease exit costs and inventory liquidation charges, as well as impairment of assets at these locations. The following table reflects the closed store and distribution center charges that relate to new closures, changes in assumptions and interest accretion:

 

		Thirteen Week Period Ended						Twenty-Six Week Period Ended
		September 1, 2018			September 2, 2017			September 1, 2018			September 2, 2017
Balance—beginning of period		$	131,182		$	155,666		$	133,290		$	165,138
Provision for present value of noncancellable lease payments of closed stores		3,201			—			11,331			913
Changes in assumptions about future sublease income, terminations and changes in interest rates		324			201			(714		)	(348		)
Interest accretion		2,556			2,907			5,241			6,002
Cash payments, net of sublease income		(15,075		)	(14,763		)	(26,960		)	(27,694		)
Balance—end of period		$	122,188		$	144,011		$	122,188		$	144,011

 

6. Fair Value Measurements

 

The Company utilizes the three-level valuation hierarchy as described in Note 5, Lease Termination and Impairment Charges, for the recognition and disclosure of fair value measurements.

 

As of September 1, 2018 and September 2, 2017, the Company did not have any financial assets measured on a recurring basis.

 

Other Financial Instruments

 

Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature.  In addition, as of September 1, 2018 and March 3, 2018 the Company has $7,217 and $7,282, respectively, of investments, carried at amortized cost as these investments are being held to maturity, which are included as a component of other assets.  The Company believes the carrying value of these investments approximates their fair value.

 

The fair value for LIBOR-based borrowings under the Company’s senior secured credit facility is estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company’s other long-term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company’s total long-term indebtedness was $3,481,831 and $3,231,901, respectively, as of September 1, 2018. There were no outstanding derivative financial instruments as of September 1, 2018 and March 3, 2018.

 

7. Income Taxes

 

The new federal tax legislation commonly referred to as the Tax Cut and Jobs Act (the “Tax Act”) enacted on December 22, 2017 (the “Enactment Date”) introduced significant changes to U.S. income tax law. Effective for tax years beginning on or after January 1, 2018, the Tax Act reduced the U.S. federal corporate income tax rate from 35% to 21%.

 

The Company recorded an income tax benefit from continuing operations of $106,559 and income tax expense of $117,450 for the thirteen week periods ended September 1, 2018 and September 2, 2017, respectively, and an income tax benefit from continuing operations of $116,056 and income tax expense from continuing operations of $105,329 for the twenty-six week periods ended September 1, 2018 and September 2, 2017, respectively. The effective tax rate for the thirteen week periods ended September 1,

 

19

Table of Contents

 

2018 and September 2, 2017 was 23.2% and 38.4%, respectively. The effective tax rate for the twenty-six week periods ended September 1, 2018 and September 2, 2017 was 22.8% and 40.9%, respectively. The effective tax rate for the thirteen and twenty-six week periods ended September 1, 2018 includes an adjustment of (4.2)% and (3.9)%, respectively, to increase the valuation allowance related to certain state deferred taxes. The tax expense for the thirteen and twenty-six week periods ended September 2, 2017 is higher in comparison to 2018, as it is based on a federal statutory rate of 35%, and includes increases to the valuation allowance primarily related to state deferred taxes.

 

The Company recognizes tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

 

The Company believes that it is reasonably possible that a decrease of up to $13,498 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months however management does not expect the change to have a significant impact on the results of operations or the financial position of the Company.

 

The Company regularly evaluates valuation allowances established for deferred tax assets for which future realization is uncertain considering historical profitability, projected taxable income, the expected timing of the reversals of existing temporary differences and tax planning strategies.  Management will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. The Company continues to maintain a valuation allowance against net deferred tax assets of $920,059 and $896,800, which relates primarily to state deferred tax assets at September 1, 2018 and March 3, 2018, respectively.

 

8. Medicare Part D

 

The Company offers Medicare Part D benefits through EIC, which has contracted with CMS to be a PDP and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes.

 

EIC is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, EIC must file quarterly and annual reports with the National Association of Insurance Commissioners (“NAIC”) and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not believe these limitations on dividends and distributions materially impact its financial position. EIC is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is $31,920 as of June 30, 2018. EIC was in excess of the minimum required amounts in these states as of September 1, 2018.

 

The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported.

 

As of September 1, 2018, accounts receivable, net included $473,211 due from CMS and accrued salaries, wages and other current liabilities included $140,992 of EIC liabilities under certain reinsurance contracts. As of March 3, 2018, accounts receivable, net included $350,563 due from CMS and accrued salaries, wages and other current liabilities included $183,318 of EIC liabilities under certain reinsurance contracts. During calendar 2017, EIC limited its exposure to loss and recovered a portion of benefits paid by utilizing quota-share reinsurance with a commercial reinsurance company. Beginning calendar 2018, EIC does not have a reinsurance agreement in place related to its individual and certain group Medicare Part D Plans.

 

9. Manufacturer Rebates Receivables

 

The Pharmacy Services Segment has manufacturer rebates receivables of $474,244 and $370,861 included in Accounts receivable, net, as of September 1, 2018 and March 3, 2018, respectively.

 

20

Table of Contents

 

10. Goodwill and Other Intangible Assets

 

Goodwill and indefinitely-lived assets, such as certain trademarks acquired in connection with acquisition transactions, are not amortized, but are instead evaluated for impairment on an annual basis at the end of the fiscal year, or more frequently if events or circumstances indicate it may be more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, the Company performs a quantitative goodwill impairment test. The fair value estimates used in the quantitative impairment test are calculated using an average of the income and market approaches. The income approach is based on the present value of future cash flows of each reporting unit, while the market approach is based on certain multiples of selected guideline public companies or selected guideline transactions. The approaches, which qualify as Level 3 within the fair value hierarchy, incorporate a number of market participant assumptions including future growth rates, discount rates, income tax rates and market activity in assessing fair value and are reporting unit specific. If the carrying amount exceeds the reporting unit’s fair value, the Company recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. In addition, the Company considers the income tax effect of any tax deductible goodwill when measuring a goodwill impairment loss.

 

During the thirteen week period ended September 1, 2018, the Company lowered its outlook for fiscal 2019.  Based upon the change in outlook, the Company determined that a quantitative goodwill impairment assessment was required.  The quantitative assessment concluded that the carrying amount of the Pharmacy Services segment exceeded its fair value principally due to a reduction of the projected growth for its business compared to the growth assumptions used in the Company’s previous assessment. This resulted in a goodwill impairment charge of $312,985 ($235,698 net of the related income tax benefit) during the thirteen-week period ended September 1, 2018, which adjusted the carrying amount of the Pharmacy Services segment to its fair value of $1,849,949.  As of September 1, 2018 and March 3, 2018, the accumulated impairment losses for the Pharmacy Services segment was $574,712 and $261,727, respectively.

 

Below is a summary of the changes in the carrying amount of goodwill by segment for the fiscal years ended September 1, 2018 and March 3, 2018:

 

		Retail Pharmacy			Pharmacy Services			Total
Balance, March 3, 2018		$	43,492		$	1,377,628		$	1,421,120
Goodwill impairment		—			(312,985		)	(312,985		)
Balance, September 1, 2018		$	43,492		$	1,064,643		$	1,108,135

 

The Company’s intangible assets are primarily finite-lived and amortized over their useful lives. Following is a summary of the Company’s finite-lived and indefinite-lived intangible assets as of September 1, 2018 and March 3, 2018.

 

		September 1, 2018											March 3, 2018
		Gross Carrying Amount			Accumulated Amortization			Net			Remaining Weighted Average Amortization Period		Gross Carrying Amount			Accumulated Amortization			Net			Remaining Weighted Average Amortization Period
Favorable leases and other (a)		$	375,817		$	(317,972	)	$	57,845		7 years		$	379,355		$	(316,798	)	$	62,557		7 years
Prescription files		908,563			(817,427		)	91,136			3 years		900,111			(801,706		)	98,405			3 years
Customer relationships(a)		388,000			(172,010		)	215,990			13 years		465,000			(172,635		)	292,365			15 years
CMS license		57,500			(7,321		)	50,179			22 years		57,500			(6,172		)	51,328			23 years
Claims adjudication and other developed software		58,985			(26,816		)	32,169			4 years		58,985			(22,617		)	36,368			5 years
Trademarks		20,100			(6,399		)	13,701			7 years		20,100			(5,394		)	14,706			8 years
Backlog		11,500			(11,500		)	—			0 years		11,500			(10,286		)	1,214			1 years
Total finite		$	1,820,465		$	(1,359,445	)	$	461,020				$	1,892,551		$	(1,335,608	)	$	556,943
Trademarks		19,500			—			19,500			Indefinite		33,500			—			33,500			Indefinite
Total		$	1,839,965		$	(1,359,445	)	$	480,520				$	1,926,051		$	(1,335,608	)	$	590,443

 

(a)                                   Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

 

21